Navigation Links
Gentium's Defibrotide Seen as Active in Multiple Myeloma

NEW YORK--(BUSINESS WIRE)--Jun 27, 2007 - Gentium S.p.A. (Nasdaq: GENT) announced the presentation of both clinical and preclinical data that support the safety, activity, synergy and potential mechanism of action of Defibrotide in combination with anticancer therapy in multiple myeloma. Investigators presented both an update from the Company's ongoing Phase I/II clinical trial for patients with refractory or relapsed multiple myeloma with Defibrotide in combination with chemotherapy, as well as a pre-clinical study demonstrating the downregulation of a key regulatory enzyme supporting a novel mechanism of action for Defibrotide in myeloma. Data from both studies was presented at the XI International Myeloma Workshop in Kos, Greece, 25-30 June, 2007.

In the first study, investigators led by Dr Antonio Palumbo of The Italian Multiple Myeloma Study Group, presented data from an ongoing multi-center, phase I/II clinical trial for relapsed or refractory multiple myeloma patients. This study is being conducted in an effort to define the maximum tolerated dose (MTD), safety and potential efficacy of the combination of melphalan, prednisone, thalidomide and Defibrotide (MPTD). Nineteen patients, who received at least three cycles of MPTD were evaluable for toxicity and response. Three escalating dose levels of Defibrotide were evaluated in combination with standard doses of melphalan, prednisone and thalidomide. No other thromboprophylaxis was administered. After a median of 3 cycles, the major response rate, including complete and partial remission was 53% (1CR, 1nCR and 7PR). Responses were seen in all three Defibrotide dose levels. Follow up remains limited and the durability of response appears favorable. MTD was not reached in any cohort. Hematological toxicities (greater than/equal to Grade 3) included neutropenia (47%), thrombocytopenia (10%), anemia (21%), non-hematological toxicities greater than/equal to grade 3 were observed in less than 5% of patients. Impor tantly only one DVT has been seen to date and no significant peripheral neuropathy has been reported.

In a preclinical study presented by Dr. Cinara Echart, Gentium's Manager of Molecular Biology, at the same meeting, Defibrotide demonstrated the ability to significantly downregulate heparanase gene expression and activity in myeloma cell lines in a dose dependent manner (p less than 0.01). In addition, Defibrotide decreases the myeloma cell invasion through the Matrigel matrix in vitro by 50%. Elevated heparanase expression in humans has been correlated with advanced progression and metastasis of many tumor types, including myeloma. Heparanase acts as a key mechanism for breakdown of extracellular matrix to facilitate tumor invasion and metastasis.

Dr. Antonio Palumbo commented, "The combination of MPTD is promising both in terms of activity and tolerability with the low rate of DVT being especially interesting. Moreover, the preclinical studies with Defibrotide are intriguing, suggesting a wider role for this drug as an orally biovavailable agent in combination with chemotherapy as a potential treatment for multiple myeloma."

About Gentium

Gentium, S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the research, development and manufacture of drugs to treat and prevent a variety of vascular diseases and conditions related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted a Fast Track Designation by the U.S. FDA to treat Severe VOD in recipients of stem cell transplants, Orphan Drug status by the U.S. FDA to treat and prevent VOD and Orphan Medicinal Product Designation by the European Commission to treat and prevent VOD.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements." In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results may differ, possibly materially, from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in our Form 20F filed with the Securities and Exchange Commission under the caption "Risk Factors."

Contact

Gentium
Gary Gemignani, 212-332-1666
Chief Financial Officer
ggemignani@gentium.com


'"/>




Related medicine technology :

1. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
2. Gentiums Defibrotide Highlighted in Two Poster Presentations at American Association for Cancer Research Annual Meeting
3. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
4. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
5. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
6. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
7. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
8. Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkins Lymphoma Appears Safe and Active in a Phase I/II Study
9. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
10. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
11. Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
Breaking Medicine News(10 mins):